Breast cancer questions on USMLE love “pattern recognition”: who’s at risk, what’s the presentation, what does pathology show, and where does it spread. This is your one-page, quick-hit cheat sheet—the stuff you want in your head walking into test day.
The 10-second big picture (what exam writers test)
- Most breast cancers are adenocarcinomas arising from ductal/lobular epithelium.
- Sporadic cases are most common, but BRCA1/2 mutations are the classic board-tested hereditary cause.
- Lymphatic spread tends to hit axillary nodes first; hematogenous spread loves bone.
Visual mnemonic: “B.R.E.A.S.T.” (quick mental checklist)
B – BRCA + family history
R – Retract (skin/nipple) + peau d’orange
E – Estrogen exposure (unopposed/longer lifetime)
A – Axillary nodes (spread)
S – Serous/bloody nipple discharge (think Paget/intraductal)
T – Triple-negative (basal-like, aggressive)
One-liner: Breast cancer = malignant ductal/lobular epithelium presenting as a hard, irregular, often painless mass with potential skin/nipple changes and axillary spread.
High-yield risk factors (USMLE loves these)
Major risks
- Female sex, increasing age
- Family history of breast/ovarian cancer (especially first-degree relatives)
- BRCA1/BRCA2 mutations
- BRCA1: commonly triple-negative, higher grade, aggressive
- BRCA2: also breast cancer risk (male breast cancer association is classic)
Estrogen exposure (think: “more cycles”)
- Early menarche, late menopause
- Nulliparity or first birth after age 30
- Postmenopausal obesity (↑ aromatization of androgens → estrogens in adipose)
Other classic associations
- Ionizing radiation (especially chest irradiation at a young age)
- Alcohol (dose-related risk)
Presentations you should instantly recognize
- Painless, firm, immobile, irregular mass
- Nipple retraction or skin dimpling (traction on Cooper ligaments)
- Peau d’orange (lymphatic obstruction/edema)
- Unilateral nipple discharge (especially bloody/serous)
- Eczematous nipple changes → think Paget disease of the breast (underlying DCIS or invasive cancer)
Must-know pathology table (cheat sheet core)
| Entity | Key histology/feature | Typical clue | Metastasis / receptor notes |
|---|---|---|---|
| Invasive ductal carcinoma (most common) | Malignant ducts in desmoplastic stroma; “hard” mass | Irregular, firm mass; may calcify | Variable ER/PR/HER2 |
| Invasive lobular carcinoma | Single-file infiltration; may have signet-ring cells | Often subtle, can be bilateral/multifocal | Classically loss of E-cadherin |
| DCIS | Malignant cells confined to ducts; may have comedonecrosis | Microcalcifications on mammogram | Premalignant; can progress |
| LCIS | Lobular proliferation, usually incidental | Often found on biopsy; no calcifications typically | Marker of ↑ risk in either breast; loss of E-cadherin |
| Paget disease of breast | Malignant cells in epidermis of nipple | Eczematous nipple/areola, pruritus | Underlying DCIS or invasive cancer likely |
| Inflammatory breast cancer | Tumor emboli in dermal lymphatics | Rapidly progressive erythema + peau d’orange | Aggressive; often no discrete mass |
| Phyllodes tumor | Leaf-like architecture; stromal proliferation | Large, fast-growing breast mass | Can be benign/malignant; hematogenous spread if malignant |
| Fibroadenoma (benign but tested) | Well-circumscribed, mobile | “Rubbery,” young women | Not a carcinoma; important ddx |
Receptors & therapeutics (Step 1 + Step 2 staples)
ER/PR positive
- Biology: hormone-driven
- Treatment concept: block estrogen signaling
- Tamoxifen (SERM) in premenopausal or as appropriate
- Aromatase inhibitors (e.g., anastrozole, letrozole) commonly postmenopausal
Tamoxifen adverse effects (must-know):
- Endometrial cancer risk (agonist in endometrium)
- Thromboembolism
- Hot flashes
HER2 positive
- Biology: amplification/overexpression of ERBB2
- Treatment: trastuzumab (± pertuzumab)
Trastuzumab adverse effect:
- Cardiotoxicity (classically ↓ LVEF / heart failure risk)
Triple-negative (ER−/PR−/HER2−)
- Often BRCA1-associated, “basal-like”
- Tends to be more aggressive, fewer targeted options → chemo/immunotherapy context (beyond Step 1 detail)
Spread patterns: where it goes (high-yield anatomy)
Lymphatic spread
- Most often to axillary lymph nodes
- Also internal mammary nodes (medial tumors)
Hematogenous spread
- Bone (classic), lungs, liver, brain
- Bone metastases often cause osteolytic lesions → pain + fractures + ↑ Ca possible
Screening & diagnosis pearls (USMLE-style workflow)
- Screening mammography picks up microcalcifications (especially DCIS)
- Definitive diagnosis requires biopsy
- Core needle biopsy is common to confirm malignancy and assess receptors (ER/PR/HER2)
Don’t confuse:
- Mammogram finds it; biopsy proves it.
“Trapdoor” differentials they like to mix in
- Fibrocystic change: cyclic pain, “lumpy-bumpy,” benign; can have calcifications but clinical context differs
- Mastitis (lactational): fever + tenderness; usually S. aureus; improves with antibiotics, not persistent mass
- Breast abscess: fluctuant, tender
- Fat necrosis: post-trauma/surgery; can mimic carcinoma on imaging
Microcalcifications quick guide (exam-friendly)
- DCIS: classic association with microcalcifications
- Benign conditions can calcify too—biopsy resolves ambiguity.
Rapid-fire USMLE one-liners (memorize)
- Skin dimpling/nipple retraction = tumor pulls on Cooper ligaments.
- Peau d’orange = dermal lymphatic obstruction (edema).
- Invasive lobular carcinoma = single-file cells + loss of E-cadherin.
- Paget disease = eczematous nipple + underlying DCIS/invasive cancer until proven otherwise.
- Trastuzumab = HER2 blockade + cardiotoxicity.
- Tamoxifen = ER modulation + endometrial cancer + DVT risk.
One-page memory anchor (last-minute cram list)
Most common: invasive ductal
Sneaky histology: lobular = single-file, no E-cadherin
Skin changes: peau d’orange, retraction (Cooper ligaments)
Nodes: axillary first
Calcifications: think DCIS
Receptors: ER/PR (tamoxifen), HER2 (trastuzumab), triple-negative (BRCA1; aggressive)